PRAX Praxis Precision Medicines

Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference

Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 9:10 a.m. ET.

The fireside chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at . A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit  and follow us on  and .



Investor Contact:
Alex Kane
Praxis Precision Medicines
 
617-300-8481

Media Contact:
Ian Stone
Canale Communications
 
619-849-5388
EN
02/08/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Praxis Precision Medicines

 PRESS RELEASE

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nas...

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on August 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,875 shares of its common stock to thr...

 PRESS RELEASE

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines to Participate in Upcoming Fireside Chat BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST. The event will be webcast live and the registration link can be found . ...

 PRESS RELEASE

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines to Participate in Upcoming Fireside Chat BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST. The registration link can be found . About Praxis  Praxis Precision Medicines is a clinica...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch